Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2005

View Archived Issues

Antipsychotic effects of a new 5-HT2C receptor agonist from Pfizer

Curcumin and its metabolite highlighted as promising agents for neurologic disorders

JNJ-27291199, an Hdm2:p53 complex inhibitor, potentiates doxorubicin

NSC-67657: A CEBPalpha activator with antileukemic potential

Tanabe updates pipeline progress in H1 FY2005

Oscient files Factive sNDA for five-day treatment of new indications

Pfizer exercises option to NicOx collaborative compounds

Myriad Genetics and Abbott extend pharmacogenetics alliance

First patient enrolled in European phase III trial of Alzhemed

Large multivalent immunogen vaccine active in melanoma, renal cell carcinoma

Tocilizumab study results reveal efficacy in arthritis, systemic lupus erythematosus

Golimumab improves signs and symptoms of refractory rheumatoid arthritis

Oral cFMS kinase inhibitor GW-2580 inhibits CSF-1 signaling in vivo

ALK5 inhibition attenuates profibrotic signaling and fibrogenic response

Flow-induced arterial remodeling modified by cavtratin

Novartis reports novel CCR1 antagonists with activity in experimental arthritis

Clevudine demonstrates sustained activity in chronic hepatitis B patients

Lassa fever vaccine candidate developed

ENMD-1198 to enter clinical testing in 2006

Emergent BioSolutions tests single dose oral typhoid vaccine in Vietnam

Genzyme acquires Cell Genesys' San Diego manufacturing operation

Phase IIb HCV study to evaluate celgosivir plus Pegetron

ChemoCentryx seeks clearance to begin clinical studies of CCX-915

Enrollment begins in phase III Viprinex study for ischemic stroke

Phase III Oxytrex results in moderate to severe osteoarthritic pain

Allergan proposes to acquire Inamed

Xyrem approved to treat excessive daytime sleepiness in narcolepsy patients

Approvable letter for Vasovist

Pexelizumab fails to meet primary endpoint threshold for statistical significance

Recent Merck KGaA patent claims novel anticoagulant agents

Cardiovascular agents disclosed in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...